Background: Bladder cancer is the most common urogenital tumor with substantial morbidity, high recurrence rate and mortality. miRNAs, a class of endogenous noncoding RNA, were found to involve in the genesis, maintenance and metastasis of cancer. Genomic profiling revealed that miR-302b is down-regulated in bladder cancer while its functions in bladder cancer remain to be ascertained. Methods: Cell functional assays including wound healing assay, CCK-8 assay, Transwell assay and flow cytometry assay were performed to clarify the functions of miR-302b expression in cell proliferation, migration, invasion and apoptosis in BC. Furthermore, RT-qPCR was performed to study the expression of miR-302b in bladder cancer tissues and the prognostic value of altered miR-302b expression with 48 formalin-fixed paraffinembedded bladder urothelial carcinoma samples.
Introduction
Bladder cancer (BC), ranking the first in urogenital malignant tumor incidence and the ninth most common malignancy worldwide, is characterized by high morbidity and mortality rates with estimated 429,800 new cases and 165,100 deaths in 2012 worldwide [1] [2] [3] . Established risk factors for the genesis of BC include genetic and molecular abnormalities, chronic stimulation and chemical or environmental exposures [4] . Roughly 75% of BC patients are non-muscleinvasive BC and 60%-70% of non-muscle-invasive BC patients will experience recurrence [1, 5] . Therefore, it is significant to explore a novel molecular biomarker for early diagnosis, treatment and recurrence prediction of BC.
MicroRNAs(miRNAs), short and endogenous noncoding RNA with roughly 19-24 nucleotides in length, regulate the gene expression by base-pairing with the 3′ untranslated region (UTR) of target mRNAs, resulting in repression of the target Genes or inhibition of protein synthesis [6, 7] . More than a thousand miRNAs were found in the human genome and one miRNA is probably involved in regulating hundreds of mRNAs [7] [8] [9] [10] . In recent years, there has been a growing emphasis on the role of miRNAs in the early diagnosis, treatment and recurrence prediction of cancer. MiRNAs play a significant role in regulating molecular pathways associated with angiogenesis, the epithelial-mesenchymal transition, cancer-stem-cell biology, metastasis and drug resistance in numerous type of tumors [8, 11] .
MiR-302b, one of the miR-302/367 cluster that is vertebrate-specific and highly conserved, is located at 4q25 chromosome region and serves as a tumor suppressor in ovarian cancer, hepatocellular carcinoma, pleural mesothelioma and gastric cancer [12] [13] [14] [15] [16] . MiR-302b had been reported to be down-regulated in a genomic profiling of miRNAs in BC [17] . However, the expression of miR-302b in BC has been not yet ascertained by reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) and the role of miR-302b in BC has not been clarified so far. In our study, RT-qPCR was performed to study the expression of miR-302b in BC and the cell functions were also evaluated by wound healing assay, CCK-8 assay, Transwell assay and flow cytometry assay. Moreover, the significance of miR-302b in the recurrence of BC was analyzed with 48 FFPE bladder urothelial carcinoma samples.
Materials and methods

Human tissue samples collection
A total of 39 paired urothelial carcinoma and adjacent non-carcinoma bladder tissues (3 cm far away from the BC tissue) were collected from patients who had received surgical bladder resection at Peking University Shenzhen Hospital (Shenzhen, China). None of the patients received any pre-operative chemotherapy or radiotherapy. The study was approved by the Ethics Committees of Peking University Shenzhen Hospital and Informed consents were obtained from the 39 patients. Once collected, all tissue samples were immediately submerged in RNAlater® RNA Stabilization Agent (Qiagen, Hilden, Germany) and frozen in liquid nitrogen afterwards until RNA extraction.
Cell culture and cell transfection
The normal transitional epithelial cell (SV-HUC-1) and BC cell lines (RT4, J82, UM-UC-3, 5637 and T24), purchased from Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China), were cultured in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) or Dulbecco's modified Eagle's medium (DMEM) (Gibco; Thermo Fisher Scientific. Inc., Waltham, MA, USA), which is added with 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc.), 1% antibiotics (100 μl/ml penicillin and 100 mg/ml streptomycin sulfates) and 1% glutamine. All cells were maintained in 37°C in a 5% CO 2 incubator. For transfection, 5637 and UM-UC-3 cells were sown in a 6-well plate and transfected with 100 pmol miR-302b mimic (F: 5′-ACUUUAACAUGGAAGUGCUUUC-3′; R: 5′-UAAGUGCUUCCAUGUU UUAGUAG-3′), inhibitor(5′-GAAAGCACUUCCAUGUUAAAGU-3′), negative control(NC, F:5′-UCACAACCUCCUAGAAAGAGUAGA-3′; R: 5′-UCACAACCUCCUAGAAAGAGUAGA-3′), inhibitor NC(5′-UCUACUC UUUCUAGGAGGUUGUGA-3′) when they are at 60%-70% confluence by using Lipofectamine 3000 (Invitrogen Life Technologies). Cells were transfected for 4-6 h at 37°C. The transfection efficiency was authenticated by RT-qPCR.
RNA extraction, cDNA synthesis and RT-qPCR
The isolation and purification of total RNA of the tissues and cells depended on TRIzol (Invitrogen; Thermo Fisher Scientific, Inc.) and the RNeasy Maxi kit (Qiagen GmbH) respectively according to the instructions of manufacturers. A total of 1 μg RNA was reverse transcribed into cDNA using miScript Reverse Transcription kit II (Qiagen GmbH). After that, the synthetic cDNA was subjected to RT-qPCR with primers and miScript SYBR® Green PCR kit (Qiagen GmbH) on the Roche Lightcycler 480 Real-Time PCR system (Roche Diagnostics, Basel, Switzerland). U6 acted as an internal control. RT-qPCR conditions were set as follows: 95°C for 15 min, after that, 40 cycles of 94°C for 15 s, 55°C for 30 s and 70°C for 30 s. The expression level of miR-302b was calculated with 2 −ΔΔCq method [18] .
Wound healing assay
Cell migration ability was assessed by wound healing assay. Succinctly, once the transfected cells reached 90%-95% confluence in 6-well plates, a straight wound was artificially scratched by a disposable 200 μl pipette tip. The detached cells were removed by phosphate-buffered saline (PBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and afterwards, the cell was maintained in humidified incubator at 37°C containing 5% CO 2 . The images of wound closure were photographed at 0 and 24 h with a digital camera system (Olympus Corporation, Tokyo, Japan). The migration distance is the furthest distance that the cells migrate to the clear area.
Transwell assay
Cell migratory and invasive ability was assessed by using Transwell chambers (BD Biosciences, New York, NJ, USA) coated with Matrigel (for invasion) or without Matrigel (for migration) following the manufacturer's protocol. At 24 h post transfection, the harvested cells were counted, suspended in 200 μl serum free DMEM and added into the top chamber. The bottom chamber was imbued with 500 μl DMEM medium containing 10% FBS. After incubation for 24 h (migration) or 36 h (invasion), the migrated or invaded cells were fixed with formaldehyde and stained with crystal violet. The cells were counted in five different fields using a microscope (Olympus Corporation, Tokyo, Japan).
Cell counting kit-8 (CCK-8) assay
Cell proliferation was assessed by CCK-8 (US Everbright Inc.) assays using an ELISA microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Approximately 3000 transfected cells were seeded in each well of 96-well plates and incubated for 0, 24, 48 or 72 h. According to the manufacturer's protocol, the cells of each well was added with 10ul CCK-8 (US Everbright Inc.) and cultured for at 37°C for 1 h before the optical density (OD) was determined at 450 nm by microplate reader.
Flow cytometry assay
Apoptosis was assessed by flow cytometry assay on Beckman Coulter (EPICS XL-4; Inc., Brea, CA, USA). In this assay, a six-well plate was used and seeded with 3 × 10 5 cells (per well). At 48 h post transfection with 100 pmol of miR-302b mimic, inhibitor or corresponding NC, all transfection cells were stained with propidium iodide (PI; Invitrogen; Invitrogen; Thermo Fisher Scientific, Inc.) and Annexin Vfluorescein isothiocyanate (FITC; Invitrogen; Invitrogen; Thermo Fisher Scientific, Inc.) for 15 min. Afterwards, the cells were added with binding buffer (400 μl/tube) and subjected to flow cytometry(EPICS Xl-4, Beckman Coulter, Brea, CA, USA). FlowJo software (version, X) fl (FlowJo LLC, Ashland, OR) was used to calculate the apoptosis rate.
Formalin-fixed paraffin-embedded (FFPE) bladder urothelial carcinoma tissue specimens
The significance of miR-302b in the recurrence of BC was analyzed with 48 FFPE bladder urothelial carcinoma tissue samples. Hematoxylin/eosin staining was performed to identify tumor areas and nonmalignant areas. All the cases were pathologically reviewed and diagnosed with urothelial carcinoma. The first recurrent tumor was defined as any tumor identified following a disease-free remission period, > 90 days after the date of initial primary bladder tumor diagnosis. The smoking patient was defined as the patient who smoked at least 500 cigarettes. After obtained from Department of pathology of Peking University Shenzhen Hospital, the FFPE bladder urothelial carcinoma tissues samples were treated with the miRNeasy FFPE Kit (Qiagen) for the total RNA extraction. All the bladder urothelial carcinoma patients of the FFPE samples received surgical bladder resection at Peking University Shenzhen Hospital between 2013 and 2015. Clinical stage of tumors was defined by the 6th AJCC TNM staging system, are presented in Table 1 .
Statistical analysis
The experiments were performed over three times in triplicate. The comparison of miR-302b expression in tissues was assessed using Paired t-test. One-way analysis of variance and then Dunnett's post hoc test was performed to analyze the relative expression of miR-302b in BC cells. Student's t-test was used to analyze assays for characterizing phenotypes of cells. The analysis of the relation between miR-302b expression and clinicopathological variables was performed by Student's t-test, Fisher's exact test or Pearson Chi-square test. The univariate and multivariate analysis of the first recurrence time were performed using Cox-proportional hazards regression analysis. Recurrence-free curves were plotted by the Kaplan-Meier method and evaluated by log-rank test. All data were analyzed by SPSS 19.0 statistical software package (SPSS, Inc., Chicago, IL, USA) and presented as the mean ± SD. P ≤ 0.05 was considered significance.
Results
MiR-302b was down-regulated in BC tissues and cell lines
The expression of miR-302b in BC tissues and cell lines were detected using RT-qPCR. Compared with adjacent non-carcinoma bladder tissues, miR-302b is down-regulated in 74.36% (29 of 39) of BC tissues and mean relative expression of miR-302b was 0.254 (P < 0.01) times in BC tissues ( Fig. 1A and Fig. 1B) . Next, significant down-regulation of miR-302b was observed in BC cell lines (Fig. 1C) .
Validation of cell transfection efficiency
The results of RT-qPCR indicated that a 62.03% (P < 0.01) and 67.49% (P < 0.15) down-regulation of miR-302b expression was observed in 5637 and UM-UC-3 cell transfected with miR-302b inhibitor compared with the inhibitor NC, respectively. In addition, a 153.01 (P < 0.001) and 110.84 (P < 0.001) times higher of miR-302b expression was observed in 5637 and UM-UC-3 cell transfected with miR302b mimic compared with the NC, respectively (Fig. 1D) .
3.3. MiR-302b inhibited 5637 and UM-UC-3 cell proliferation CCK-8 assay was conducted on whether miR-302b inhibits the proliferation ability of BC. Data from CCK-8 assay revealed that the
Fig. 2. The results of CCK-8 assay in 5637 and UM-UC-3 cells. (A) 5637 cells transfected with miR-302b mimic vs NC and (B) miR-302b inhibitor vs inhibitor NC. (C) UM-UC-3 cells transfected with miR-302b mimic vs NC and (D) miR-302b inhibitor vs inhibitor NC. CCK-8, Cell
Counting Kit 8; NC, negative control; OD, optical density. *P < 0.05, **P < 0.01, ***P < 0.001. The migration distance of UM-UC-3 cells transfected with miR-302b mimic vs NC and miR-302b inhibitor vs inhibitor NC. The migration distance is the furthest distance that the cell migrates to the clear area. miR, microRNA; NC, negative control. *P < 0.05, **P < 0.01, ***P < 0.001. speed of proliferation was slowed down in 5637 ( Fig. 2A) and UM-UC-3 ( Fig. 2C) cell transfected with miR-302b mimic compared with the NC, respectively. Opposite results were obtained after transfection with miR-302b inhibitor. The speed of proliferation was increased in 5637 ( Fig. 2B) and UM-UC-3 ( Fig. 2D) cell transfected with miR-302b inhibitor compared with the inhibitor NC, respectively. The results demonstrated that miR-302b inhibited cell proliferation in BC.
MiR-302b inhibited 5637 and UM-UC-3 cell mobility
Wound healing assay and Transwell assay were conducted on whether miR-302b inhibits the mobility of BC. The data from images of the wounds revealed that the distance of migration was significantly reduced in 5637 cell transfected with miR-302b mimic compared with the NC (P < 0.01), while it was significantly increased when transfected with miR-302b inhibitor compared with the inhibitor NC(P < 0.01, Fig. 3B ). The same results were obtained in the experiment in UM-UC-3 cell (Fig. 3C) . Data from Transwell assay revealed that up-regulation of miR-302b suppressed 5637 and UM-UC-3 cell migration and invasion. The number of 5637 ( Fig. 4B and Fig. 4C ) and UM-UC-3 ( Fig. 4D and Fig. 4E ) cell invaded and migrated to the bottom chamber significantly reduced in the group transfected with miR-302b mimics compared with the corresponding control group. However, the effects were reversed when suppressing the expression of miR-302b. These results demonstrated that miR-302b inhibited cell mobility of BC.
MiR-302b induced 5637 and UM-UC-3 cell apoptosis
Flow cytometry assay was conducted on whether miR-302b induced the apoptosis of BC. Data of flow cytometry assay revealed that the apoptosis of 5637 cells (Fig. 5B) transfected with miR-302b mimics was significantly increased compared with the NC (P < 0.01), while the apoptosis of 5637 cells transfected with miR-302b inhibitor was significantly decreased compared with the inhibitor NC (P < 0.001). Similar results were obtained in UM-UC-3 cells (Fig. 5C, P < 0.01) . These results demonstrated that miR-302b induced BC cell apoptosis.
MiR-302b acted as a potential biomarker to predict recurrence in bladder urothelial carcinoma
As shown in Table 1 , no significance was found between miR-302b expression and gender, age, smoking, tumor size, tumor number and clinical stage except for tumor grade. The expression of miR-302b in the patients with poor-differentiated bladder urothelial carcinoma is lower than that in the patients with well-differentiated bladder urothelial carcinoma (P = 0.034). The recurrence-free curves of univariate analysis showed that patients with low expression of miR-302b had a remarkable increased risk of recurrence (HR = 2.735, 95% CI = 1.149-8.507, P = 0.023, Table 2 ). In the multivariate analysis models(including gender, age, smoking, tumor size, tumor number, clinical stage and tumor grade), higher risk of recurrence was associated with having low miR-302b levels with HR 3.799 and 95% CI The cells were counted in five different fields using a microscope. miR, microRNA; NC, negative control. *P < 0.05, **P < 0.01, ***P < 0.001.
1.525-9.459 (P = 0.004, Table 2 ). The Kaplan-Meier recurrence-free curves revealed that patients with low expression of miR-302b had a remarkable increased risk of recurrence (P = 0.017, Fig. 6 ). These results indicated that miR-302b acted as a potential biomarker to predict recurrence in bladder urothelial carcinoma. . FlowJo software (version, X) was used to calculate the apoptosis rate and quadrant 3 was the apoptotic cell. NC, negative control. PI, propidium iodide; FITC, fluorescein isothiocyanate. *P < 0.05, **P < 0.01, ***P < 0.001.
Discussion
The genesis of BC is multi-step and multi-stage process associated with the mobilization of oncogene and the silence of anti-oncogene. As one of the most financially burdensome tumor, bladder cancer is a common malignancy with high rate of recurrence [19] . Molecular data indicate that most recurrences are associated with failures of definitive treatment [20] . Therefore, identification a novel molecular biomarker for early diagnosis, treatment and recurrence prediction of BC has taken on epic importance for us. Modulation of miRNA expression is cumulatively recognized as a crucial mechanism by which anti-oncogene proteins and oncoproteins exert part of their functions [8] . miRNAs hold the key to the regulation of tumor genesis, progression and metastasis via interaction with target genes in the tumor cells [21] . More and more miRNAs are shown to be correlated with genesis and evolution of BC, such as miR-210-3p, miR-139-5P and miR-145 [22] [23] [24] .
MiR-302b was found to be down-regulated in various types of cancers, including gastric adenocarcinoma [25] , hepatocellular carcinoma [13] , ovarian cancer [14] . In our study, result of RT-qPCR showed that miR-302b was sharply down-regulated in BC tissues and cell lines, which was consistent with previous result of genomic profiling [17] . In order to further investigate the role of miR-302b in BC, Transwell assay, wound healing assay, CCK-8 assay and flow cytometry assay were performed, which revealed that over-expression of miR302b suppressed 5637 and UM-UC-3 cell proliferation, mobility and induced apoptosis while these effects were reversed when the expression of miR-302b was reduced. The results demonstrated that miR-302b can regulate BC cell functions. The prognosis analysis including cox proportional hazard regression analysis and Kaplan-Meier curve demonstrated that the patients with low expression of miR-302b experienced high risks of recurrence. Interestingly, Smoking seems to contribute to the recurrence of bladder urothelial carcinoma patient in the cox proportional hazard regression multivariate analysis as the P value is 0.050.
MiR-302b was well documented on its tumor suppresser role in various types of cancers. In osteosarcoma, miR-302b was down-regulated and played a tumor repressor role in the invasion and migration by inhibiting the expression of Runx2 [26] . Result of Bo et al. [16] demonstrated that novel tumor suppressor miR-302b-3p blocked the growth of gastric cancer cell via AKT Pathway by binding to the 3′ UTR of IGF-1R. The role of miR-302b in hepatocellular carcinoma was no exception, in which up-regulation of miR-302b contributed to the inhibition of invasion, proliferation and metastasis, indicating that miR302b might represent a novel target for hepatocellular carcinoma treatment [13, 27] . Moreover, miR-302b was shown to be down-regulated in ovarian cancer and correlated with the inhibition of cell proliferation and colony formation, as well as the promotion of apoptosis, which was achieved by targeting RUNX1 [14] .
Previous studies had shown that miR-302b mediates drug response and itself is modulated in therapy. Result of Lin et al.. [28] . Revealed that miR-302b level was significantly decreased in P-glycoproteinoverexpressing breast cancer cells and overexpression of miR-302b sensitized breast cancer cells to adriamycin by means of inhibiting Pglycoprotein (P-gp) via MAP/ERK kinase kinase 1. Another study about breast cancer suggested that miR-302b sensitized tumor cells to cisplatin though the negative regulation of E2F1, reducing the viability and proliferation of tumor cells [29] . In hepatocellular carcinoma, upregulation of miR-302b increased the sensitivity to 5-FU in tumor cells, which might be put down to targeting Mcl-1 and DPYD, representing a prospective candidate as therapeutic strategy for conquering chemotherapy resistance [30] .
MiR-302b was well documented as novel biomarker for the diagnosis and prognosis of cancer or other disease. Yang et al. [31] . Found that plasma miR-302b level was obviously reduced in patients with acute myocardial infarction (AMI) and ROC analysis demonstrated that plasma miR-302b can accurately diagnose AMI, suggesting that miR- 302b may be a promising biomarker for diagnosis of early AMI. In addition, gastric cancer patients with down-regulation of miR-302b tended to have fierce cancer progression and ominous prognosis, demonstrating miR-302b serving as an independent potential prognostic biomarker for gastric cancer patients [32] . Moreover, miR-302b was shown to be significantly down-regulated in esophageal squamous cell carcinoma and correlated with tumor differentiation as well as lymph node metastasis; univariate and multivariate analyses demonstrated that miR-302b was a novel promising molecular marker for the prognosis of esophageal squamous cell carcinoma [33] . The limitation of our research is that the sample size in our analysis about whether miR-302b can act as a biomarker for recurrence prediction in bladder urothelial carcinoma is limited and the same analysis in a large of sample size should be performed. Moreover, the relevant signaling pathways and target of miR-302b in BC, and whether miR302b can act as a biomarker for the early diagnosis in bladder cancer hasn't been clarified. Using three database (TargetScan, miRanda and RNA22), EPS8 is selected as a potential target that is regulated by miR302b. And it would be explored in our further study.
Conclusion
The results of the present study indicated that miR-302b is reduced in BC tissues and BC cell lines. Further study suggested that overexpression of miR-302b suppresses cell mobility, proliferation, and induces cell apoptosis, while opposite results were obtained after inhibiting the expression of miR-302b. The prognosis analysis including cox proportional hazard regression analysis and Kaplan-Meier curve demonstrated that the patients with low expression of miR-302b experience high risks of recurrence. These results demonstrate that miR302b regulates cell functions and acts as a potential biomarker to predict recurrence in bladder cancer.
